Cemex S.A.B. de C.V. Sponsored ADR vs TransMedics Group Inc — how do they compare? Cemex S.A.B. de C.V. Sponsored ADR trades at $9.56 (market cap $13.84B), while TransMedics Group Inc trades at $79.33 (market cap $2.81B). The key difference: Cemex S.A.B. de C.V. Sponsored ADR is far larger — about 4.9× TransMedics Group Inc's market cap, and Cemex S.A.B. de C.V. Sponsored ADR pays a 1.3% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cemex S.A.B. de C.V. Sponsored ADR for 0 Days and TransMedics Group Inc for 24 Days on average.
| CX | TMDX | |
|---|---|---|
Market Cap | $13.84B | $2.81B |
Volume | 6,589,714 | 962,415 |
Sector | Basic Materials | Health |
52-Week High | $13.55 | $150.42 |
52-Week Low | $9.12 | $61.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $19.83B | $3.21B |
Dividend Yield | 1.3% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TransMedics Group (TMDX) trades at $81.07, up 0.98% on the day, but remains in a technical downtrend with a bearish moving average signal. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying but also multiple legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 analyst target but faces near-term headwinds from earnings misses and legal overhangs. Key risks include execution pressure from heavy investments and ongoing legal scrutiny, while the core organ transplant technology business maintains a growth trajectory.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Cemex produces, distributes, markets, and sells cement, ready-mix concrete, aggregates, and other construction materials. Its operations serve markets around the world.
Read more on CX →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →